Abbott profit more than doubles as medical device sales rebound By Reuters

<iframe src=”//″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>

© Reuters. FILE PHOTO: Boxes of Abbott’s heart stents are pictured inside a store at a hospital in New Delhi, India, April 27, 2018. Picture taken April 27, 2018. REUTERS/Adnan Abidi

(Reuters) -Abbott Laboratories’ quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical device sales.

The medical device maker and its rivals, Quest Diagnostics (NYSE:) and Becton Dickinson (NYSE:) and Co, banked on soaring sales of COVID-19 tests last year to cushion a lockdown-driven hit to their mainstay businesses.

But with curbs lifted and vaccinations gathering pace, demand for medical devices is returning as more people opt for non-urgent procedures.

Second-quarter sales in Abbott’s diagnostics business grew nearly 63% to $3.25 billion, with COVID-19 testing-related sales at $1.3 billion, down from the previous quarter.

The company recorded sales growth of more than 11%, excluding COVID testing, on an organic basis in the quarter compared to pre-pandemic levels.

It maintained its 2021 adjusted earnings forecast of $4.30 to $4.50 per share from continuing operations.

The company’s net earnings rose to $1.19 billion, or 66 cents per share, in the quarter ended June 30, from $537 million, or 30 cents per share, a year earlier.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


77 + = 82